Veligrotug, an anti-IGF-1R antibody, has shown significant efficacy in reducing proptosis and diplopia in both active and chronic thyroid eye disease (TED) in phase 3 clinical trials (THRIVE, THRIVE-2).
The regimen offers a shortened infusion protocol—five infusions at three-week intervals, each lasting 30 minutes—compared to teprotumumab, potentially improving patient convenience and adherence.
Safety profile is manageable, with mild adverse events predominating and rates of hearing impairment similar to other IGF-1R inhibitors.
Veligrotug has received Breakthrough Therapy designation from the FDA, expediting its review as an alternative to teprotumumab.
